Key result
Individualized antiplatelet therapy guided by platelet function testing significantly decreased the risk of MACCE compared with standard therapy (OR 0.58; 95% CI 0.43-0.77) in patients after PCI.
Why the study?
It remains controversial whether individualized antiplatelet therapy guided by platelet function test can improve prognosis in patients after PCI.
Does individualized antiplatelet therapy guided by platelet function test reduce major adverse cardiovascular and cerebrovascular events in patients after percutaneous coronary intervention?
Population
16,835 patients after PCI from 22 studies
Comparison
PFT-guided individualized antiplatelet therapy vs standard antiplatelet therapy
Design
Systematic review and meta-analysis
Authors
Loading...
Supports PFT-guided therapy post-PCI; confirms MACCE benefit in Level 1 meta-analysis.
Meta-Analysis (n=16,835)
Does individualized antiplatelet therapy guided by platelet function test reduce major adverse cardiovascular and cerebrovascular events in patients after percutaneous coronary intervention?
Odds Ratio: 0.58 (95% CI 0.43–0.77)
Individualized antiplatelet therapy guided by platelet function testing reduces MACCE without increasing bleeding risk in post-PCI patients.
Peng et al. (2023) conducted a meta-analysis in percutaneous coronary intervention (n=16,835). Individualized antiplatelet therapy guided by platelet function test (PFT) vs. Standard antiplatelet therapy was evaluated on major adverse cardiovascular and cerebrovascular events (MACCE) (OR 0.58, 95% CI 0.43-0.77). Individualized antiplatelet therapy guided by platelet function testing significantly decreased the risk of MACCE compared with standard therapy (OR 0.58; 95% CI 0.43-0.77) in patients after PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: